Zurich Insurance Group Ltd FI Buys 3,832 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Zurich Insurance Group Ltd FI boosted its position in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 1.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 205,015 shares of the biotechnology company's stock after acquiring an additional 3,832 shares during the quarter. Zurich Insurance Group Ltd FI owned 0.27% of Axon Enterprise worth $60,324,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Axon Enterprise by 2.7% during the first quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company's stock valued at $2,547,878,000 after buying an additional 212,401 shares during the last quarter. Sands Capital Management LLC grew its stake in shares of Axon Enterprise by 0.6% during the fourth quarter. Sands Capital Management LLC now owns 2,628,652 shares of the biotechnology company's stock valued at $679,060,000 after buying an additional 16,347 shares during the last quarter. Motley Fool Asset Management LLC grew its stake in shares of Axon Enterprise by 238.7% during the first quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company's stock valued at $153,981,000 after buying an additional 346,838 shares during the last quarter. 1832 Asset Management L.P. grew its stake in shares of Axon Enterprise by 44.0% during the second quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company's stock valued at $110,546,000 after buying an additional 114,800 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Axon Enterprise by 13.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 368,732 shares of the biotechnology company's stock valued at $108,496,000 after buying an additional 45,049 shares during the last quarter. Institutional investors own 79.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on AXON shares. Barclays increased their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an "overweight" rating in a report on Wednesday, August 7th. JMP Securities increased their target price on shares of Axon Enterprise from $375.00 to $430.00 and gave the stock an "outperform" rating in a report on Thursday, September 12th. Needham & Company LLC reiterated a "buy" rating and set a $400.00 target price on shares of Axon Enterprise in a report on Wednesday, August 7th. Bank of America started coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They set a "buy" rating and a $380.00 target price for the company. Finally, Northland Securities increased their target price on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an "outperform" rating in a report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $365.38.

Insider Transactions at Axon Enterprise

In other news, Director Matthew R. Mcbrady sold 2,000 shares of Axon Enterprise stock in a transaction on Friday, August 9th. The shares were sold at an average price of $364.66, for a total transaction of $729,320.00. Following the transaction, the director now owns 4,892 shares in the company, valued at approximately $1,783,916.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Matthew R. Mcbrady sold 2,000 shares of the firm's stock in a transaction on Friday, August 9th. The shares were sold at an average price of $364.66, for a total transaction of $729,320.00. Following the sale, the director now directly owns 4,892 shares in the company, valued at approximately $1,783,916.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the firm's stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $373.03, for a total transaction of $167,863.50. Following the sale, the director now owns 7,379 shares in the company, valued at $2,752,588.37. The disclosure for this sale can be found here. Insiders have sold 317,981 shares of company stock worth $115,662,734 in the last 90 days. 6.10% of the stock is currently owned by insiders.

Axon Enterprise Stock Performance

AXON stock traded up $1.60 on Wednesday, hitting $395.26. The company had a trading volume of 521,567 shares, compared to its average volume of 521,033. Axon Enterprise, Inc. has a 12-month low of $189.12 and a 12-month high of $397.32. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The stock's 50-day simple moving average is $351.23 and its 200 day simple moving average is $318.36. The stock has a market cap of $29.87 billion, a price-to-earnings ratio of 115.11, a P/E/G ratio of 10.56 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.18. The business had revenue of $504.00 million for the quarter, compared to analysts' expectations of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company's revenue was up 34.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.80 EPS. As a group, equities research analysts expect that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.